C

CSL

Develops and delivers biotherapies and vaccines

Global Procurement Category Lead Engineering and Construction

Full-TimeUpdated on 10/23/2026
No salary listed
Expert
Master's, MBA
Remote in USA+56 moreMore locations: Remote in Canada | Remote in Bolivia | Remote in Martinique | Remote in Guadeloupe | Remote in Puerto Rico | Remote in Panama | Remote in Aruba | Remote in Bahamas | Remote in Bermuda | Remote in Venezuela | Remote in Uruguay | Remote in Barbados | Remote in Nicaragua | Remote in Ecuador | Remote in El Salvador | Remote in Falkland Islands (Malvinas) | Remote in Turks and Caicos Islands | Remote in Virgin Islands, British | Remote in Saint Martin (French part) | Remote in Saint Barthélemy | Remote in Saint Kitts and Nevis | Remote in Bouvet Island | Remote in Grenada | Remote in Trinidad and Tobago | Remote in Guyana | Remote in Paraguay | Remote in Cayman Islands | Remote in Mexico | Remote in Peru | Remote in Chile | Remote in Honduras | Remote in Bonaire, Sint Eustatius and Saba | Remote in Saint Lucia | Remote in Belize | Remote in Sint Maarten (Dutch part) | Remote in Dominican Republic | Remote in South Georgia and the South Sandwich Islands | Remote in Greenland | Remote in Colombia | Remote in Virgin Islands, U.S. | Remote in Antigua and Barbuda | Remote in Saint Pierre and Miquelon | Remote in Argentina | Remote in Jamaica | Remote in French Guiana | Remote in Saint Vincent and the Grenadines | Remote in Dominica | Remote in Cuba | Remote in Haiti | Remote in Curaçao | Remote in Montserrat | Remote in Guatemala | Remote in Suriname | Remote in Brazil | Remote in Anguilla | Remote in Costa Rica
RemoteRemote within the Americas; domestic travel as required (10–30%) and international travel as required (10–20%), varying by incumbent location.
Operations & LogisticsProcurement & Sourcing

About the job

Requirements
  • A Master's degree in Engineering is preferred; a postgraduate business degree or MBA is highly regarded.
  • At least 12 years of experience in strategic sourcing, other relevant sourcing experience, or equivalent experience in engineering and construction management.
  • At least 2 years of senior leadership experience, preferably with a global team.
  • At least 5 years of global team management experience.
  • Strong communication and influencing skills and the ability to deal with ambiguity and build bridges.
  • Strong understanding of the A&E/EPC/EPCM and CQV/CSV categories and business.
  • Understanding of the pharmaceutical industry or a related industry is preferred but not essential.
  • Basic strategic orientation; inquisitiveness; comfort with ambiguity; and self-motivation to identify trends and improvement opportunities aligned with business objectives and strategic plans.
  • Strong executive presence, demonstrated leadership and collaboration skills, and the ability to build effective relationships and influence peers and key stakeholders.
  • Demonstrated ability to organize and lead global teams.
  • Strong project management skills, including planning tasks, assigning resources, managing progress, removing barriers, managing change, resolving conflict, building consensus, and motivating team members across multiple projects concurrently.
  • Strong verbal and written communication skills, including tailoring messages to the audience, presenting information clearly and concisely, applying creative approaches to engage audiences, managing change, resolving conflict, and building consensus.
  • Solid knowledge of Category Management, Strategic Sourcing, and Supplier Relationship Management.
  • Ability to build and maintain strong relationships and collaborate effectively across all organizational levels and functions.
Responsibilities
  • Develop and implement global category strategies aligned with corporate and relevant business strategies, with clear objectives and action plans for Global Category Management Lead roles to reduce total cost of ownership and risk while increasing innovation, customer service, compliance, and quality.
  • Drive collaboration with business units on complex problem resolution, investigative data analytics, process reengineering, and establishing sustainable programs that meet global needs consistently across affected company areas.
  • Lead and manage projects that redesign global strategy, business models, and ways of working; drive year-over-year financial improvements while ensuring operational excellence.
  • Define and implement effective category management strategies; establish and manage councils for business-critical commodities aligned with evolving business requirements; and lead key sourcing activities, including negotiations, to improve cost of ownership, risk, quality, and supply performance.
  • Lead complex business negotiations with major suppliers and advise regional sourcing as required.
  • Conduct business ethically and in compliance with applicable laws, regulations, anti-bribery requirements, and company standards; support diversity and inclusion by promoting use of small, disadvantaged, and diverse suppliers.
  • Establish and manage supplier relationship management processes according to supplier segmentation, including risk management strategies aligned with global policies, to enhance supplier relationships and innovation, deliver required supply, quality, service, and continuous improvement, and minimize costs; develop measures of value beyond savings.
  • Implement global procedures to ensure sourcing activities comply with the CSL Sourcing Policy, Code of Responsible Business Practices, and other compliance standards.
  • Adhere to CSL Supplier Risk Management policies and procedures and use supplier risk management tools as appropriate.
  • Monitor supply performance key performance indicators and conduct regular operational reviews under Procurement governance processes, supported by analysis and reporting from the Centre of Excellence; ensure category management team roles also review and manage supplier performance against agreed standards.
  • Lead, motivate, and develop Procurement employees, including long-term talent development, succession planning, and performance management to support employees in meeting or exceeding expectations while demonstrating company values.
  • Build and maintain professional relationships with senior internal stakeholders and senior external executives at large vendors through ongoing discussions and participation in formal teams and groups to manage supplier performance, issues, procurement improvement initiatives, and broader business issues.
  • Lead and participate in global transformation projects and continuous improvement initiatives to deliver targeted benefits.
  • Travel domestically as required (10–30%) and internationally as required (10–20%); requirements vary depending on where the incumbent is based.
Desired Qualifications
  • Understanding of the pharmaceutical industry or a related industry is preferred but not essential.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.